“…Four studies 33 , 34 , 36 , 37 selected untreated AML, and the other 35 involved patients with relapsed AML. In Part II, eight studies 11 , 15 , 19 , 21 , 23 – 25 , 27 used sorafenib, four 13 , 14 , 29 , 30 used quizartinib, four 18 , 22 , 26 , 28 used midostaurin, two 16 , 17 used sunitinib, one 20 used lestaurtinib, one 31 used crenolanib, and one 12 used multiple types of FLT3 inhibitors. In one study, 18 ORR included not only CR, CRi, CRp, and PR but also hematologic improvement (HI) and blast response (BR).…”